Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Ticker
$VRDN
Sector
Primary listing
Employees
252
Headquarters
Website
VRDN Metrics
BasicAdvanced
$2bn
-
-$3.37
0.82
-
Price and volume
Market cap
$2bn
Beta
0.82
52-week high
$34.29
52-week low
$13.18
Average daily volume
2.2m
Financial strength
Current ratio
15.148
Quick ratio
14.712
Long term debt to equity
8.272
Total debt to equity
8.388
Interest coverage (TTM)
-49.07%
Profitability
EBITDA (TTM)
-385.234
Gross margin (TTM)
-378.92%
Net profit margin (TTM)
-508.46%
Operating margin (TTM)
-543.86%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-33.25%
Return on equity (TTM)
-58.14%
Valuation
Price to revenue (TTM)
23.458
Price to book
3.76
Price to tangible book (TTM)
3.76
Price to free cash flow (TTM)
-5.475
Free cash flow yield (TTM)
-18.26%
Free cash flow per share (TTM)
-3.375
Growth
Revenue change (TTM)
23,382.78%
Earnings per share change (TTM)
1.09%
3-year revenue growth (CAGR)
250.00%
3-year earnings per share growth (CAGR)
-10.96%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Benzinga·5 days ago
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Business Wire·1 week ago
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs